Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/69—Boron compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

• compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell (T reg cell) function comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, CXCR4 receptor inhibitors, and/or
• heterobifunctional inhibitors which comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
• One such disease, disorder, and/or condition is cancer.
• cancer tumors are not masses of solely malignant cells, but instead comprise some malignant cells and some recruited normal cell types. Liu et al., “Targeting Regulatory T Cells in Tumors,” FEBS J. 283:2731-48, at 2731 (2016). The malignant cells and normal cells both play roles in promoting tumor growth and metastasis. Id. One of the normal cells that supports cancer progression in the tumor microenvironment are Treg cells.
• Treg cells down-regulate other immune cells, thereby playing an important role in, for example, preventing autoimmunity.
• malignant cells can attract T reg cells and increase the local concentration of cytokines expressed by Treg cell that down-regulate other immune cells.
• T reg cells are induced and maintained by immunoregulatory receptors, such as PD-1.
• T reg cells also respond to homing signals within the inflamed tumor microenvironment that include the endothelial ceil surface protein, E-selectin, and the CXCR4 ligand, SDF-1. Using these pathways, the cancer cells use T reg cells to prevent other immune cells from attacking the cancer.
• the immune system is often able to produce a response against the malignancy, due at least in part to the influence of T ⁇ cells, this response is often insufficient to eliminate the tumor.
• T-cell checkpoint inhibitors may be useful in treating cancer, but the course of treatment is usually lengthy and there are several side-effects.
• T-cell checkpoint inhibitors only target one aspect of the cancer cells' commandeering of the immune system - the inducement and maintenance of T reg cells - and it does not address the recruitment of the T cells to the tumor microenvironment by E-selectin and/or SDF-1.
• compositions and treatments for suppressing T reg cell function for the treatment of cancer in particular, compositions and treatments that address the E-selectin and/or SDF-1 related pathways.
• additional compositions and treatments for suppressing Tng cell function for the treatment of other diseases, disorders, and/or conditions related to over-active or numerous Treg cells such as bacterial and viral infections including sepsis, septic conditions, and HIV infection.
• Figure 1 is a graph of the mean tumor growth, shown as mean tumor burden in mm 3 , in 12 groups of experimental mice (control groups included as well), with standard error.
• Figure 2 is a graph of the median tumor growth, shown as median tumor burden in mm 3 , in 12 groups of experimental mice (control groups included as well), with standard error.
• Figures 3A-D are graphs of the tumor growth of individual mice of group 1 (saline control group, Fig. 3A); group 2 (GMI-1359 treatment, Fig. 3B); group 3 (isotype control antibody LTF-2, Fig. 3C); and group 4 (anti-PD-L1 antibody treatment, Fig. 3D), shown as tumor burden in mm 3 and including control median and group median.
• Figures 4A-D are graphs of the tumor growth of individual mice of group 5 (GMI-1359 and LTF-2 antibody, Fig. 4A); group 6 (GMI-1359 and anti-PD-L1 antibody treatment, Fig. 4B); group 7 (saline control, Fig. 4C); and group 8 (GMI- 1359 treatment, Fig. 4D), shown as tumor burden in mm 3 and including control median and group median.
• Figures 5A-D are graphs of the tumor growth of individual mice of group 9 (LTF-2 antibody, Fig. 5A); group 10 (anti-PD-L1 antibody treatment, Fig. 5B); group 11 (GMI-1359 and LTF-2 antibody, Fig. 5C); and group 12 (GMI-1359 and anti-PD- L1 antibody treatment, Fig. 5D), shown as tumor burden in mm 3 and including control median and group median.
• Figure 6 is a graph of the percent mean body weight change for 12 experimental groups (control groups included as well), with standard error.
• Figure 7 is a graph of the percentage of CD4 + /CCR7 + /CD62L + cells in tumors for the individuals in experimental groups 7 through 12.
• Figure 8 is a graph of the percentage of CD87CCR77CD62L+ cells in tumors for the individuals in experimental groups 7 through 12.
• Figure 9 is a graph of the percentage of CD11b + /GR1 + cells in tumors for the individuals in experimental groups 7 through 12.
• Figure 10 is a graph of the percentage of CD4 + /CD25 + /FoxP3 + cells (T reg cells) in tumors for the individuals in experimental groups 7 through 12.
• Figure 11 is a graph of the percentage of CD47CCR77CD62L+ cells in spleens for the individuals in experimental groups 7 through 12.
• Figure 12 is a graph of the percentage of CD87CCR77CD62L* cells in spleens for the individuals in experimental groups 7 through 12.
• Figure 13 is a graph of the percentage of CD11b7GR1 + cells in spleens for the individuals in experimental groups 7 through 12.
• Figure 14 is a graph of the percentage of CD4 + /CD25 + /FoxP3 + cells (T reg cells) in spleens for the individuals in experimental groups 7 through 12.
• Figures 15A-C are representative scatter plots showing the Tmg cells in tumors of an individual (mouse 5, group 10) treated with anti-PD-L1 antibody treatment (Fig. 15A); an individual (mouse 5, group 11) treated with GMI-1359 and LTF-2 antibody (Fig. 5B); and an individual (mouse 5, group 12) treated with GMI- 1359 and anti-PD-L1 antibody treatment (Fig. 15C).
• Figures 16A-B are representative scatter plots showing the
• Figures 17A-B are representative scatter plots showing the
• Figures 18A-C are representative scatter plots showing the CD11 b + /GR1 + cells in tumors of an individual (mouse 3, group 9) treated with LTF-2 antibody treatment (Fig. 18A); an individual (mouse 3, group 12) treated with GMI-1359 and anti-PD-L1 antibody (Fig. 18B) and presenting with a stable disease state; and an individual (mouse 4, group 12) treated with GMI-1359 and anti-PD-L1 antibody treatment (Fig. 15C) and presenting with a progressive disease state.
• Figure 19 is a table of the toxicity and efficacy data for the 12 treatment groups.
• Figure 20 is a comparison of the complete response (CR) rate and the median days post treatment until to complete response for group 7 (anti-PD-L1 antibody treatment alone) and group 12 (GMI-1359 and anti-PD-L1 antibody treatment combined).
• Figure 21 is a table showing the competitive binding activity (IC50) of GMI- 1359 against E-selectin and CXCR4.
• Figure 22 displays graphs of the percentages of CD4+, CD8+ and
• Figure 23 is a table that shows the ratio of CD8/regulatory T cells in spleen and tumor tissue samples, in vivo, on study day 5, in each treatment group.
• Figure 24A shows a mean tumor burden group comparison and response summary table.
• Figure 24B is a graph that shows the number of days post tumor implant on the x-axis, and the mean tumor burden (mm 3 ) in each treatment group, on the y- axis.
• E-selectin is a cell adhesion molecule that is expressed on activated endothelial cells and plays an important role in leukocyte recruitment to the site of injury.
• ⁇ -selectin inhibitor includes inhibitors of E-selectin only, as well as inhibitors of E-selectin and either P-selectin or L-selectin, and inhibitors of E-selectin, P-selectin, and L-selectin.
• non-glycomimetic moiety includes moieties having a structure not intended to mimic a carbohydrate molecule.
• a non-glycomimetic moiety may not be (and is typically not) active as an E selectin antagonist.
• non- glycomimetic moieties are generally moieties added to a glycomimetic moiety for purposes of altering at least one property, such as solubility, bio-availability, lipophilicity and/or other drug-like properties of the glycomimetic.
• T reg cells are a subpopulation of T cells which modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease.
• T ⁇ cells are immunosuppressive and generally suppress or downregulate induction and proliferation of other T cells.
• T regs cells express the biomarkers CD4, CD25, and FoxP3 (i.e., are CD4*/CD25 + /FoxP3 + ).
• T-cell checkpoints are molecules that need to be activated or inactivated to start an immune response.
• T-cell checkpoint inhibitors are agents that prevent or inhibit the normal T- cell checkpoint operation and prevent an immune response.
• PD-1 cell death protein 1
• PD-1 usually prevents the T cells from attacking normal body cells because normal body cells present the PD-L1 (the ligand that binds to PD-1).
• the PD-1 checkpoint protein attaches to the PD-L1 protein of a cell, the T cell does not attack that cell.
• a T-cell checkpoint inhibitor may block the PD-L1 protein presented on the cancer cells (or it may block the PD-1 of the T-cells) to prevent the T-cell's PD-1 from binding to the PD-L1. If the PD-1 and PD-L1 binding is blocked, the T-cell does not recognize the cell as "self," and may attack the cell. Accordingly, a T-cell checkpoint inhibitor may assist the immune system in attacking cancer cells that present PD-L1 proteins. Examples of T-cell checkpoint inhibitors are known in the art, including anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTL antibodies.
• patient refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
• subject any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
• the patient, subject or individual is a human.
• the term “therapy” refers to “treating” or “treatment” of a disease or condition including inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease).
• “Therapy” may also refer to prophylactic treatment, which includes preventing or delaying the onset of the disease or condition from occurring in a subject that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease.
• the compounds may be administered in any order (e.g., a T-cell checkpoint inhibitor administered first followed by an E-selectin inhibitor or an E-selectin inhibitor administered first followed by an E-selectin inhibitor, etc.).
• treatment means the slowing down, interruption, arrest, reversal or stoppage of the progression of the disease, which does not necessarily require the complete elimination of all the signs and symptoms of the disease.
• treatment is intended to mean that a statistically significant proportion of patients can be treated effectively, in such a way that the symptoms and clinical signs show at least an improvement.
• the person skilled in the art can easily establish whether the proportion is statistically significant using various statistical methods (e.g. confidence intervals, determination of them p value, Student's t-test, Mann-Whitney test etc.). Confidence intervals have a confidence of at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
• the p values are 0.1, 0.05, 0.01, 0.005 or 0.0001.
• a method for treatment and/or prevention of at least one disease, disorder, or condition comprising administering to a subject in need thereof (1) an effective amount of at least one T- cell checkpoint inhibitor and (2) an effective amount of at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor.
• At least one of (1 ) the at least one T-cell checkpoint inhibitor and (2) the at least one other inhibitor is in the form of at least one pharmaceutical composition.
• the at least one pharmaceutical composition further comprises at least one pharmaceutically acceptable ingredient.
• the at least one T-cell checkpoint inhibitor is in the form of a first pharmaceutical composition and the at least one other inhibitor is in the form of a second pharmaceutical composition.
• a method for treatment and/or prevention of at least one bacterial infection, viral infection, or condition relating to at least one bacterial or viral infection comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one other inhibitor chosen from E- selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor.
• the Infection is an HIV infection.
• the condition relating to a bacterial or viral infection is sepsis or septic conditions.
• a method for treatment and/or prevention of at least one cancer comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor.
• a method for treatment and/or prevention of at least one disease, disorder, or condition in which suppression of Treg cells comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one other inhibitor chosen from E-selectin inhibitors, CXCR4 receptor inhibitors, and heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor.
• a method for treatment and/or prevention of at least one disease, disorder, or condition in which suppression of T reg cells is desired comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one E-selectin inhibitor and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one E- selectin inhibitor.
• a method for treatment and/or prevention of at least one disease, disorder, or condition in which suppression of T ⁇ cells is desired comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one CXCR4 receptor inhibitor and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one CXCR4 receptor inhibitor.
• a method for treatment and/or prevention of at least one disease, disorder, or condition in which suppression of T reg cells is desired comprising administering to a subject in need thereof (1) an effective amount of at least one T-cell checkpoint inhibitor and an effective amount of at least one heterobifunctional inhibitor that comprises at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, and/or (2) an effective amount of at least one pharmaceutical composition comprising at least one T-cell checkpoint inhibitor and at least one heterobifunctional inhibitor that comprises at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor.
• any T-cell checkpoint inhibitors can be used in the compositions and methods disclosed herein.
• the at least one T-cell checkpoint inhibitor targets the PD-1 receptor and/or the CTLA-4 protein on T ree cells.
• the at least one T-cell checkpoint inhibitor is a PD-L1 inhibitor.
• the at least one T-cell checkpoint inhibitor is the anti-mPD-L1 antibody.
• the at least one T-cell checkpoint inhibitor is chosen from nivolumab and ipilimumab.
• the E-selectin inhibitors which include the at least one E-selectin inhibitor herein, may be chosen from glycomimetics.
• the E-selectin inhibitors are chosen from sialyl Lewis x (sLe x ) and sLe* mimetics.
• the E-selectin inhibitors are chosen from small molecule glycomimetic antagonists of E-selectin, antibodies directed to E-selectin, aptamers to E-selectin, peptides directed to E-selectin, and peptidomimetics directed to E-selectin.
• the E-selectin inhibitors are chosen from compounds of Formula (I):
• R 1 is chosen from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 8 haloalkyl, C 2 -C 8 haloalkenyl, and C 2 -C 8 haloalkynyl groups;
• R 2 is chosen from H, -M, and -L-M;
• Y 1 is chosen from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, d- ⁇ haloalkyl, C 2-8 haloalkenyl, C 2-8 haloalkynyl, C 6-18 aryl, and C 1 -13 heteroaryl groups;
• R 4 is chosen from -OH and -NZ 1 Z 2 groups, wherein Z 1 and Z 2 , which may be identical or different, are each independently chosen from H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 8 haloalkyl, C 2 -C 8 haloalkenyl, and C 2 -C 8 haloalkynyl groups, wherein Z 1 and Z 2 may together form a ring;
• R 5 is chosen from C 3 -C 8 cycloalkyl groups
• R 6 is chosen from -OH, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1-8 haloalkyl, C 2 -C 8 haloalkenyl, and C 2 -C 8 haloalkynyl groups;
• R 7 is chosen from -CH 2 OH, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2-8 alkynyl, C 1 -C 8 haloalkyl, C 2 -C 8 haloalkenyl, and C 2 -C 8 haloalkynyl groups;
• R 8 is chosen from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 8 haloalkyl, C 2-8 haloalkenyl, and C 2 -C 8 haloalkynyl groups;
• L is chosen from linker groups
• the E-selectin inhibitors are chosen from:
• CXCR4 receptor inhibitors CXCR4 chemokine receptor inhibitors
• SDF-1 inhibitor SDF-1 antagonist
• SDF-1 antagonist an agent inhibits the binding of the chemokine SDF-I to an SDF-I ligand (e.g., prevents the binding of SDF-I to CXCR4).
• Such inhibitors will typically prevent the binding of stromal derived factor-1 (SDF-1) to a CXCR4 receptor.
• SDF-1 stromal derived factor-1
• Examples of CXCR4 chemokine receptor inhibitors are AMD-3100
• the CXCR4 receptor inhibitors are chosen from petpides, diketopiperazine mimetics, bicyclams, tetrahydroquinolines,
• the CXCR4 receptor inhibitors are chosen from AMD-3100, ALX40-4C, T134, and T22 peptide.
• heterobifunctional inhibitors are chosen from compounds of Formula (II):
• R 1 is chosen from H, Ci_8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C-i-e haloalkyl, C 2 . 8 haloalkenyl, and C 2-8 haloalkynyl groups;
• R 4 is chosen from C 3-8 cycloalkyl groups
• R 5 is independently chosen from H, halo, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, C 24 haloalkenyi, and C 2-8 haloaikynyl groups;
• n is chosen from integers ranging from 1 to 4.
• L is chosen from linker groups.
• heterobifunctional inhibitors are chosen from compounds of Formula (lla):
• the linker groups of Formula I and/or Formula II are independently chosen from groups comprising spacer groups, such spacer groups as, for example, -(CH 2 ) P - and -0(CH 2 ) P -, wherein p is chosen from integers ranging from 1 to 30. In some embodiments, p is chosen from integers ranging from 1 to 20.
• spacer groups include carbonyi groups and carbonyl- containing groups such as, for example, amide groups.
• a non-limiting example of a spacer group is
• the linker groups are independently chosen from
• At least one linker group is
• At least one linker group is
• At least one linker group is chosen from
• the at least one E-selectin inhibitor is chosen from compounds of Formula (la):
• n is chosen from integers ranging from 1 to 100. In some embodiments, n is chosen from 4, 8, 12, 16, 20, 24, and 28.
• the E-selectin inhibitors are chosen from E-selectin inhibitors disclosed in U.S. Patent No. 9,109,002, which is hereby incorporated by reference.
• the E-selectin inhibitor is GMI-1271. See, e.g., Price et al., "Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone," Science Translational Medicine, Vol. 8(340), May 25, 2016, [DOI:10.1126/scitranslmed.aad4059]; Dutta et al., "E- Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in
• heterobifunctional inhibitors are chosen from compounds of the following Formulae:
• heterobifunctional inhibitors are chosen from compounds of the following Formulae:
• the heterobifunctional inhibitors are chosen from heterobifunctional inhibitors disclosed in U.S. Patent No. 8,410,066 and
• the heterobifunctional inhibitor is GMI-1359. See, e.g., Steele, Maria M. et al., "A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI- 1359) prevents pancreatic tumor metastasis and improves chemotherapy [abstract]," Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015 Apr 18-22, Philadelphia, PA; Philadelphia (PA): AACR, Cancer Res 2015, 75(15 Suppl):Abstract nr 425. doi:10.1158/1538-7445. AM2015-425; Gravina, Giovanni L.
• the at least one disease, disorder, or condition is chosen from cancers.
• the cancers are chosen from liquid cancers (e.g., MM, ALL, and AML) and solid cancers (e.g., prostate cancer).
• the cancers are chosen from liquid cancers.
• the cancers are chosen from solid cancers.
• the subject is treated locally at a tumor of a solid cancer.
• the rate of increase of cancerous cells is reduced or halted.
• the number of cancer cells is reduced.
• the cancer cells are eliminated.
• metastasis of cancer cells reduced.
• the metastasis of cancer cells is halted.
• infiltration of the cancer into bone marrow is reduced or halted.
• the subject has cancer and has received or will receive chemotherapy and/or radiotherapy.
• the subject has cancer and has received or will receive chemotherapy and/or radiotherapy.
• chemotherapy comprises administering a therapeutically effective amount of at least one compound chosen from platinum, cisplatin, carboplatin, oxaliplatin,
• 5-fluorouracil 5-fluorouracil
• the chemotherapy comprises administration of bortezomib. In some embodiments, the chemotherapy comprises administration of gemcitabine.
• the at least one disease, disorder, or condition is chosen from a bacterial infection, a viral infection, and a condition relating to a bacterial or viral infection.
• the viral infection is an HIV infection and/or the patient has been diagnosed with AIDS or an HIV-related illness.
• the bacterial infection is sepsis and/or the subject has been diagnosed with a septic condition.
• the administration to the subject of at least one T- cell checkpoint inhibitor and the at least one other inhibitor suitably overlap so that the therapeutic effect of one agent (i.e. the time period post use where a measurable benefit to the patient is observed) is concurrent, at least at some point, with the period of therapeutic effect of the second agent.
• the at least one T-cell checkpoint inhibitor and the at least one other inhibitor are administered concurrently.
• the at least one T-cell checkpoint inhibitor and the at least one other inhibitor are administered at the different times.
• the at least one T-cell checkpoint inhibitor and the at least one other inhibitor are administered sequentially.
• the at least one T-cell checkpoint inhibitor and the at least one other inhibitor are administered in a single pharmaceutical composition.
• the at least one T-cell checkpoint inhibitor and the at least one other inhibitor are administered in separate pharmaceutical
• the pharmaceutical composition(s) further comprises at least one additional pharmaceutically acceptable ingredient.
• any one or more of the compounds of the present disclosure may be administered in the form of a pharmaceutically acceptable derivative, such as a salt, and/or it/they may also be used alone and/or in
• an "effective amount” or “therapeutically effective amount” refers to an amount of a compound of the present disclosure or a composition comprising at least one such compound that, when administered to a subject, either as a single dose or as part of a series of doses, is effective to produce at least one therapeutic effect.
• a therapeutic effect can be killing cancer cells, inducing apoptosis in cancer cells, reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to a tumor or cancer cells, promoting an immune response against cancer cells or a tumor, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer.
• Optimal doses may generally be determined using experimental models and/or clinical trials. Design and execution of pre-clinical and clinical studies for each of the therapeutics (including when administered for prophylactic benefit) described herein are well within the skill of a person of ordinary skill in the relevant art.
• the optimal dose of a therapeutic may depend upon the body mass, weight, and/or blood volume of the subject. The minimum dose that is sufficient to provide effective therapy may be used in some embodiments.
• Subjects may generally be monitored for therapeutic effectiveness using assays suitable for the disease or condition being treated or prevented, which assays will be familiar to those having ordinary skill in the art and are described herein.
• the level of a compound that is administered to a subject may be monitored by determining the level of the compound (or a metabolite of the compound) in a biological fluid, for example, in the blood, blood fraction (e.g., serum), and/or in the urine, and/or other biological sample from the subject. Any method practiced in the art to detect the compound, or metabolite thereof, may be used to measure the level of the compound during the course of a therapeutic regimen.
• the dose of a compound described herein may depend upon the subject's condition, that is, stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, and weight, and other factors apparent to a person of ordinary skill in the medical art. Similarly, the dose of the therapeutic for treating a disease or disorder may be determined according to parameters understood by a person of ordinary skill in the medical art.
• compositions may be administered in any manner appropriate to the disease or disorder to be treated as determined by persons of ordinary skill in the medical arts.
• An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as discussed herein, including the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
• an appropriate dose (or effective dose) and treatment regimen provides the pharmaceutical composition(s) as described herein in an amount sufficient to provide therapeutic and/or prophylactic benefit (for example, an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity or other benefit as described in detail above).
• compositions described herein may be administered to a subject in need thereof by any one of several routes that effectively delivers an effective amount of the compound.
• suitable administrative routes include topical, oral, nasal, intrathecal, enteral, buccal, sublingual, transdermal, rectal, vaginal, intraocular, subconjunctival, sublingual, and parenteral
• administration including subcutaneous, intravenous, intramuscular, intrasternal, intracavernous, intrameatal, and intraurethral injection and/or infusion.
• the pharmaceutical composition described herein may be sterile aqueous or sterile non-aqueous solutions, suspensions or emulsions, and may additionally comprise at least one pharmaceutically acceptable excipient (i.e., a non-toxic material that does not interfere with the activity of the active ingredient).
• a pharmaceutically acceptable excipient i.e., a non-toxic material that does not interfere with the activity of the active ingredient.
• Such compositions may be in the form of a solid, liquid, or gas (aerosol).
• the compositions described herein may be formulated as a lyophilizate, or compounds described herein may be encapsulated within liposomes using technology known in the art.
• the pharmaceutical compositions may further comprise at least one additional pharmaceutically acceptable ingredient, which may be biologically active or inactive.
• Non-limiting examples of such ingredients include buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides, amino acids (e.g., glycine), antioxidants, chelating agents (e.g., EDTA and glutathione), stabilizers, dyes, flavoring agents, suspending agents, and preservatives.
• buffers e.g., neutral buffered saline or phosphate buffered saline
• carbohydrates e.g., glucose, mannose, sucrose or dextrans
• mannitol proteins
• proteins e.g., polypeptides
• amino acids e.g., glycine
• antioxidants e.g., EDTA and glutathione
• Excipients for therapeutic use are well known, and are described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 et Ed. Mack Pub. Co., Easton, PA (2005)). In general, the type of excipient is selected based on the mode of administration, as well as the chemical composition of the active ingredient(s). Pharmaceutical compositions may be formulated for the particular mode of administration. For parenteral administration, pharmaceutical compositions may further comprise water, saline, alcohols, fats, waxes, and buffers.
• compositions may further comprise at least one ingredient chosen, for example, from any of the aforementioned excipients, solid excipients and carriers, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, kaolin, glycerin, starch dextrins, sodium alginate, carboxymethylcellulose, ethyl cellulose, glucose, sucrose, and magnesium carbonate.
• excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, kaolin, glycerin, starch dextrins, sodium alginate, carboxymethylcellulose, ethyl cellulose, glucose, sucrose, and magnesium carbonate.
• compositions may be in the form of a liquid.
• a liquid pharmaceutical composition may include, for example, at least one the following: a sterile diluent such as water for injection, saline solution, physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspending medium,
• the pharmaceutical composition comprises physiological saline.
• the pharmaceutical composition an injectable pharmaceutical composition, and in some embodiments, the injectable pharmaceutical composition is sterile.
• At least one of the compounds of the present disclosure can be used alone or in combination with at least one additive appropriate to make tablets, powders, granules and/or capsules, for example, those chosen from conventional additives, disintegrators, lubricants, diluents, buffering agents, moistening agents, preservatives, coloring agents, and flavoring agents.
• the pharmaceutical compositions may be formulated to include at least one buffering agent, which may provide for protection of the active ingredient from low pH of the gastric environment and/or an enteric coating.
• a pharmaceutical composition may be formulated for oral delivery with at least one flavoring agent, e.g., in a liquid, solid or semi-solid formulation and/or with an enteric coating.
• Oral formulations may be provided as gelatin capsules, which may contain the active compound or biological along with powdered carriers. Similar carriers and diluents may be used to make compressed tablets. Tablets and capsules can be manufactured as sustained release products to provide for continuous release of active ingredients over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
• a pharmaceutical composition may be formulated for sustained or slow release. Such compositions may generally be prepared using well known
• Sustained-release formulations may contain the active therapeutic dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Excipients for use within such formulations are biocompatible, and may also be biodegradable; the formulation may also provide a relatively constant level of active component release. The amount of active therapeutic contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release, and the nature of the condition to be treated or prevented.
• compositions described herein can be formulated as suppositories by mixing with a variety of bases, such as emulsifying bases or water- soluble bases.
• bases such as emulsifying bases or water- soluble bases.
• the pharmaceutical compositions may be prepared as aerosol formulations to be administered via inhalation.
• the compositions may be formulated into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen and the like.
• compositions comprising these compounds may be administered topically (e.g., by transdermal administration).
• Topical formulations may be in the form of a
• Topical formulations may include one or more of a penetrating agent or enhancer (also call permeation enhancer), thickener, diluent, emulsifier, dispersing aid, or binder.
• Physical penetration enhancers include, for example, electrophoretic techniques, such as iontophoresis, use of ultrasound (or "phonophoresis”), and the like.
• Chemical penetration enhancers are agents administered either prior to, with, or immediately following administration of the therapeutic, which increase the permeability of the skin, particularly the stratum corneum, to provide for enhanced penetration of the drug through the skin. Additional chemical and physical penetration enhancers are described in, for example, Transdermal Delivery of Drugs, A. F. Kydonieus (ED) 1987 CRL Press; Percutaneous Penetration Enhancers, eds. Smith et al. (CRC Press, 1995); Lenneras et a!., J. Pharm. Pharmacol. 54:499-508 (2002); Karande et al., Pharm. Res. 19:655-60 (2002); Vaddi et al., Int. J. Pharm.
• Routes of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, intrathecal, and subcutaneous routes.
• the compounds or compositions are administered locally (i.e., near a cancer tumor).
• one or more of the compounds or compositions are administered using different routes of administration.
• the compounds or pharmaceutical composition(s) can be administered in one or more doses and treatment regimens, which may be the same or different.
• each of the compounds or pharmaceutical composition(s) is administered in an amount ranging from about 1 mg/kg to about 50 mg/kg once a day.
• the dosage may be at any dosage including, but not limited to, about 1 Mg/kg, 25 pg/kg, 50 pg/kg, 75 Mg/kg, 100 Mg/kg, 125 Mg/kg, 150 Mg/kg, 175 Mg/kg, 200 Mg/kg, 225 Mg/kg, 250 Mg/kg, 275 Mg/kg, 300 Mg/kg, 325 Mg/kg, 350 Mg/kg, 375 Mg/kg, 400 Mg/kg, 425 Mg/kg, 450 Mg/kg, 475 Mg/kg, 500 Mg/kg, 525 Mg/kg, 550 Mg/kg, 575 Mg/kg, 600 Mg/kg, 625 Mg/kg, 650 Mg/kg, 675 Mg/kg, 700 Mg/kg, 725 Mg/kg, 750 Mg/kg, 775 Mg/kg, 800 Mg/kg, 825 Mg/kg, 850 Mg/kg, 875 M
• the compounds or pharmaceutical composition(s) are administered in any of these amounts and ranges once a day, more than once a day, every other day, every two days, etc.
• the at least one T- cell checkpoint inhibitor and the at least one E-selectin inhibitor, CXCR4 receptor inhibitor, and/or heterobifunctional inhibitor, wherein an E-selectin inhibitor is linked to a CXCR4 receptor inhibitor are administered concurrently and/or in the same number of treatments per day.
• the at least one T-cell checkpoint inhibitor and the at least one E-selectin inhibitor, CXCR4 receptor inhibitor, and/or heterobifunctional inhibitor, wherein an E-selectin inhibitor is linked to a CXCR4 receptor inhibitor are administered on different schedules.
• One of more treatment cycles may be repeated, and any number of cycles is contemplated.
• the number of treatments per day and the amount per dose for each compound or pharmaceutical composition may vary during each cycle.
• Kits comprising unit doses of at least one compound or pharmaceutical composition of the present disclosure, for example, in oral or injectable doses, are provided.
• Such kits may include a container comprising the unit dose, an
• T-cell checkpoint inhibitor with an E- seiectin inhibitor and/or a CXCR4 receptor inhibitor.
• the T-cell checkpoint inhibitor used was an anti-mPD-L1 antibody.
• Heterobifunctional inhibitor GMI-1359 an inhibitor of both E-selectins and CXCR4 receptors, was used.
• GMI-1359 was formulated in sterile saline.
• the vehicle sterile saline
• the formulation was then stirred overnight at 20°C.
• the final dosing solution was clear and colorless with a pH of 9.99.
• the dosing formulation was prepared fresh weekly and was stored protected from light at 20°C when not in use. Dose levels of GMI- 1359 were given as bulk drug substance.
• Anti-mPD-L1 (10F.9G2, 6.39mg/ml, Lot #5592-4-6/0615) was obtained as a clear, colorless stock solution. Upon receipt, it was stored protected from light at 4°C. The dosing solution was prepared by diluting the stock solution with PBS 1mg/ml. The final dosing solution was clear and colorless with a pH of 6.96. The formulation was prepared once weekly and was stored protected from light at 4°C when not in use. On each dosing day, the dosing formulations were stored on ice prior to and during dosing.
• CT26.WT cells were grown in RPM1 1640 medium which
• FBS Fetal Bovine Serum
• PSG Penicillin/Streptomycin/L-Glutamine
• the cells were centrifuged at 200rcf for 8 minutes at 4°C, the supernatant was aspirated, and the pellet was re-suspended in cold Dulbecco's Phosphate Buffered Saline (DPBS) by pipetting. An aliquot of the homogeneous cell suspension was diluted in a trypan blue solution and counted using a Luna automated cell counter. The preimplantation cell viability was 92%. The cell suspension was centrifuged at 200rcf for 8 minutes at 4°C. The supernatant was aspirated and the cell pellet was re-suspended in cold serum-free medium to generate a final concentration of 2.50E+06 trypan-excluding cells/ml. The cell suspension was maintained on wet ice during implantation. Following implantation, an aliquot of the remaining cells was diluted with a trypan blue solution and counted to determine the post-impiantation cell viability (91%).
• DPBS Dulbecco's Phosphate Buff
• Test animals were implanted subcutaneously, high in the axilla Gust under the fore limb) on Day 0 with 5.00E+05 cells in 0.2ml of serum-free medium using a 27-gauge needle and syringe.
• mice were sorted into study groups based on
• Groups 1 and 7 The Vehicle Control (saline) was dosed intraperitoneal!;/, every day for 20 days (Days 3-22) and every day for 12 days (Days 3-14) for Groups 1 and 7, respectively.
• Groups 2 and 8 GMI-1359 was dosed intraperitoneally at 40mg/kg, every day for 20 days (Days 3-22) and every day for 12 days (Days 3-14) for Groups 2 and 8, respectively.
• Groups 3 and 9 Anti-KLH; Rat lgG2b, LTF-2 was dosed intraperitoneally at lOmg/kg, every 3 days for 2 treatments, with 3 days off for 2.5 weeks (Days 3, 6, 10, 13 and 17) for Group 3.
• Group 9 was dosed intraperitoneally at 10mg/kg, every 3 days for 2 treatments, with 3 days off for 2 weeks (Days 3, 6, 10 and 13).
• Groups 4 and 10 Anti-mPD-L1 , 10F.9G2 was dosed intraperitoneally at lOmg/kg, every 3 days for 2 treatments, with 3 days off for 2.5 weeks (Days 3, 6, 10, 13 and 17) for Group 4.
• Group 10 was dosed intraperitoneally at 10mg/kg, every 3 days for 2 treatments, with 3 days off for 2 weeks (Days 3, 6, 10 and 13).
• Groups 5 and 11 GMI-1359 was dosed in combination with anti-KLH; Rat lgG2b, LTF intraperitoneally at 40mg/kg and 10mg/kg, respectively.
• GMI- 1359 was dosed once a day for 20 days (Days 3-22) and anti-KLH; Rat lgG2b was given every 3 days for 2 treatments, with 3 days off for 2.5 weeks (Days 3, 6, 10, 13 and 17).
• Group 11 GMI-1359 was dosed once a day for 12 days (Days 3-14) and anti-KLH; Rat lgG2b was dosed every 3 days for 2 treatments, with 3 days off for 2 weeks and (Days 3, 6, 10 and 13).
• GMI-1359 On days when both compounds were dosed, GMI-1359 was given first and then anti-KLH; Rat lgG2b, LTF was given within minutes thereafter.
• Groups 6 and 12 GMI-1359 and anti-mPD-L1 , 10F.9G2 were dosed in a combination regimen intraperitoneally at 40mg/kg and lOmg/kg, respectively.
• GMI-1359 was dosed once a day for 20 days (Days 3-22) and anti-mPD- L1 , 10F.9G2 was given every 3 days for 2 treatments, with 3 days off for 2.5 weeks and (Days 3, 6, 10, 13, and 17).
• GMI-1359 was dosed once a day for 12 days (Days 3-14) and anti-mPD-L1 was dosed every 3 days for 2 treatments, with 3 days off for 2 weeks (Days 3, 6, 10, and 13). On days in which both compounds were given, GMI- 1359 was given first and anti-mPD-L1, 10F.9G2 was dosed within minutes thereafter.
• mice were dosed according to individual body weight on the day of treatment (0.2ml/20g).
• mice from Groups 7-12 were euthanized for tumor and spleen collection. All mice were euthanized via over exposure to carbon dioxide. The tumors and spleens were excised and placed in a labeled 5mL sampling tube filled with cold PBS and placed on ice. The tumors and spleens were provided to the Molecular Imaging's in vitro group for flow cytometric analysis.
• Mean tumor burdens of each of the test groups are shown in Figure 1.
• Median tumor burdens of each of the test groups are shown in Figure 2.
• Tumor burdens for individuals in groups 1-4, as well as the group median for each of groups 1-4, are plotted in Figures 3A-D, respectively; tumor burdens for individuals in groups 5-8, as well as the group median for each of groups 5-8, are plotted in Figures 4A-D, respectively; and tumor burdens for individuals in groups 9-12, as well as the group median for each of groups 9-12, are plotted in Figures 5A-D, respectively.
• the median tumor burden for the control group i.e., the median for group 1 (saline)
• Tumor growth delay (“T-C”)
• T-C Tumor growth delay
• the mean tumor growth for each group shown as mean tumor burden in mm 3 for the 12 experimental groups is shown in Figure 1.
• the median tumor growth for each group, shown as mean tumor burden in mm 3 for the 12 experimental groups is shown in Figure 2.
• Tumor Growth Delay (T-C) is the difference between the median times it takes the treated and control groups to reach the stated evaluation size. This is calculated from the median times to evaluation size for each animal in the group, not from interpolation of the median growth curve. Tumor growth delay results showing the statistically significant delays for this study are provided in table 1.
• mice were coded as having regressing disease if their tumor burden decreased less than 50% of that at Day 9.
• FIG. 6 provides a graph of the percent mean body weight change for the 12 experimental groups. As indicated in Figure 6 (and the Maximum Treatment Related Weight Loss column in Figure 19 indicating that all subjects gained weight), the treatments were all well-tolerated and no weight loss was observed.
• the plunger on a 3mL syringe was used to crush the spleen in 10mL DPBS until organ was well broken up and the DPBS became cloudy with cells.
• the cell suspension was then filtered with a 70 ⁇ strainer on a 50ml_ tube and washed with 20mL DPBS. The suspension was then centrifuged for 7 minutes at 300rcf and the supernatant was discarded before proceeding the red blood cell lysis.
• each of the tumor and spleen samples were re- suspended in 3mL ACK Lysis Buffer and then incubated for 5 minutes at room temperature.
• the suspension was diluted by adding 10mL DPBS, and then the cells were collected via centrifugation for 5 minutes at 300rcf.
• the cells were again re- suspended in 30mL DPBS and counted.
• the suspension was centrifuged again, and the supernatant was discarded before proceeding to the Fc block.
• each of the tumor and spleen samples were re- suspended at 1E+06 cells per 100 ⁇ L in Flow Cytometry Staining buffer with 1 ⁇ L Fc block per 1E+06 cells. The suspensions were incubated for 5 minutes at room temperature, then centrifuged for 5 minutes at 300rcf, and the supernatant was removed before proceeding to surface staining.
• T-Cells - Tumor CD4 1:1000 + CD8a 1:1000 + 5 ⁇ L CD197 + 5 ⁇ L CD62L
• T-Cells - Spleen CD4 1 :2000 + CD8a 1 :2000 + 5 ⁇ L CD197 + 5 ⁇ L CD62L
• CD11b & GR1 - Tumor CD11b 1:500 + GR1 1:1000
• CD11b & GR1 - Spleen CD11b 1:500 + GR1 1:1000
• CTLA-4 - Tumor 1 :500
• CTLA-4 - Spleen 1 :500
• CD8a & Ki67 - Tumor CD8a 1 : 1000 + Ki67 1 : 1000
• CD8a & Ki67 - Spleen CD8a 1 :2000 + Ki67 1 : 1000
• CD4 1 1000 + CD25 1 :500; FoxP3: 1 :500 in permeabilization buffer
• CD4, CD25, & FoxP3 - Spleen CD4 1 :2000 + CD25 1 :500; 1. FoxP3: 1:500 in permeabilization buffer
• the tumor and spleen cells were re-suspended at 1E+06 cells per 50 ⁇ L.
• Each of the 50 ⁇ L cell suspensions containing 1E+06 cells was added to 50 ⁇ L antibodies diluted in staining buffer in round-bottom 96-well plate. The plate was incubated for 30 minutes in the dark at room temperature on the orbital shaker, setting 2.5. The samples were diluted by adding 200 ⁇ L Flow Cytometry Staining Buffer and then centrifuged for 5 minutes at 300rcf. The supernatant was aspirated and the cells were washed wash by re-suspending in 250 ⁇ L Flow
• the cells were re-suspended in 200 ⁇ L FoxP3 Fixation/Permeabilization working solution and incubated for 30 minutes in the dark at room temperature. The samples were then centrifuged at 400rcf for 5 minutes at room temperature, then the supernatant was discarded. 200 ⁇ L 1X permeabilization buffer was added to each well. The samples were centrifuged at 400rcf for 5 minutes at room temperature, then the supernatant was discarded. 200 ⁇ L 1X permeabilization buffer was added to each well for a second time. The samples were again centrifuged at 400rcf for 5 minutes at room temperature, then the supernatant was again discarded.
• the cells were then re- suspended in 50 ⁇ - permeabilization buffer and 50 ⁇ L 1X permeabilization buffer with anti-FoxP3 or Ki67 was added. The suspension was incubated for 60 minutes in the dark at 4°C. The samples were diluted by adding 200 ⁇ L 1X permeabilization buffer, and then centrifuged for 5 minutes at 400rcf. The supernatant was removed, the cells were washed with 250 ⁇ L Flow Cytometry Staining Buffer per well, followed by centrifugation for 5min at 400rcf. The washing was repeated once (supernatant again removed, the cells washed with 250 ⁇ L Flow Cytometry Staining Buffer per well, followed by centrifugation for 5min at 400rcf).
• the cells were re-suspended in 250 ⁇ L Flow Cytometry Staining Buffer per well, and the samples are ready for Flow Cytometry Analysis.
• the 96- well plate is loaded into the Attune Autosampler.
• Several samples (from which no data were generated) were required to define the instrument settings— these include unlabeled cells for voltage optimization and gating, as well as fluorescence-minus- one controls to validate the gates.
• the workspace was customized, beginning with a side scatter (SSC) versus forward scatter (FSC) dot plot and adding relevant "daughter" plots to display fluorescence data. This initial plot was used to gate on live cells, live tumor cells, or live lymphocytes, and further analysis was performed on only the selected populations. Once the workspace was set up, the autosampler acquired data.
• SSC side scatter
• FSC forward scatter
• AbC mouse/rat beads were used. These beads contain two components: capture beads which bind to the heavy chain of any antibody generated in their designated species and negative beads with no antibody binding capacity. The beads provide very strong positive and negative signals which can be used to calculate the emission spillover between channels from fluorophores being used.
• the AbC capture beads and negative beads were re-suspended by vortexing prior to use.
• a sample tube was prepared with 1 drop of the appropriate species-specific capture beads and 50 ⁇ L antibody at the determined working dilution. The solution in the sample tube was mixed well and incubated for 15 minutes are room temperature in the dark. 3ml_ Flow Cytometry Staining Buffer was added to sample tubes to dilute antibody, and then centrifuged for 5 minutes at 200rcf. The supernatant was removed and the bead pellet was re-suspended in 500 ⁇ L Flow Cytometry Staining Buffer. One drop of negative beads was added to each tube and mixed well. The samples were then analyzed by flew cytometry.
• Figures 7-14 provide graphs of the results of the flow cytometry analysis for various markers tested In groups 7 through 12. The graphs also categorize each of the individuals in the groups as having progressive disease, stable disease, or as a tumor-free survivor.
• Figure 7 graphs the percentage of CD4 + /CCR7 + /CD62L + cells in tumors;
• Figure 8 graphs the percentage of CD8 + /CCR7 + /CD62L + cells in tumors;
• Figure 9 graphs the percentage of CD11b + /GR1 + cells in tumors;
• Figure 10 graphs the percentage of CD4 + /CD25 + /FoxP3 + cells (T reg cells) in tumors;
• Figure 11 graphs the percentage of CD4 + /CCR7 + /CD62L + cells in spleens;
• Figure 12 graphs the percentage of CD8 + /CCR7 + /CD62L + cells in spleens;
• Figure 13 graphs the percentage of CD11b + /
• Evaluation size The tumor burden (mm 3 ) selected for calculation of tumor growth delay.
• the Evaluation Size is selected from the exponential portion of the control tumor growth curve where the error of measurement tends to be minimal (usually between 500 and 1000mm 3 ).
• TFS Tumor-Free Survivors
• Rx Related Death An animal is presumed to experience a treatment- related death if it is found dead or is euthanized in moribund condition within 2 weeks of the last treatment with a tumor burden less than half that of the smallest lethal tumor in the control group and shows no evidence of infection, mechanical dosing trauma, or other obvious causes of morbidity at necropsy. This is an individual toxicity parameter. As shown in Figure 19, Rx Related Death column, all of the treatments were well tolerated as no individuals died or were euthanized as a result of any treatment.
• Tumor Doubling Time The growth rate of the tumor expressed as the volume doubling time (days). Calculated from a log-linear least squares regression of the exponential portion of the tumor growth curve. These values are used to compute tumor cell kill, fractional effect, and surviving fraction estimates. They are also used to assess the appropriateness of the biology of the tumor in this
• Therapeutic Index We define therapeutic index as simply the range of tolerated dosage levels that produce substantial anticancer activity. Substantial activity for this purpose is defined as a tumor growth delay that is ⁇ the duration of treatment and that is also statistically different from the control at the P ⁇ 0.05 level.
• Time to Evaluation Size The time (days) it takes a tumor to reach the specified Evaluation Size. Calculated from a log-linear least squares best fit of tumor burden versus time for the exponential portion of the final (post-treatment) tumor growth curve. This value is calculated for every animal in the experiment. The group medians are then used to calculate the Tumor Growth Delay. This is an individual efficacy parameter.
• Tumor Burden at Last Rx The tumor burden on the last day of treatment. This value is calculated from a log-linear least squares best fit of tumor burden versus time for the exponential portion of the final (post-treatment) tumor growth curve. (Presented to facilitate T/C comparisons.)
• this study investigated anti-tumor effects of administering at least one anti-mPD-L1 immune checkpoint inhibitor antibody and GMI-1359 as well as of administering GMI-1359 alone.
• a preliminary examination of potential changes in immune cell endpoints was undertaken.
• mice were distributed into treatment groups at the time of implant prior to a tumor being established. All animals weighed ⁇ 16.6g at the initiation of therapy. Mean group body weights for all animals at first treatment were well-matched (range 17.4-18.3g). A tumor burden of 750mm 3 was chosen for evaluation of efficacy by tumor growth delay.
• the median time to evaluation size was 15.9 days from the start of dosing (Day 3) and the median post Day 9 tumor volume doubling time for Group 1 was 3.1 days. There were no spontaneous regressions in the control group and the take rate was 100%. All mice in the Control Group were identified with progressive disease. The median time to progression was on Day 11.6 and the progression free survival period was 2.6 days.
• the average percentage of T-cells detected in the Group 7 tumors via flow cytometry was 7.52% CD4 + cells and 23.83% CD8 + cells. There was an average of 4.14% myeloid-derived suppressor cells (MDSCs) and 3.37% regulatory T-cells (Tregs) in the tumors. The average percentages of cells expressing PD-1, PD-L1, and CTLA-4 were 28.07%, 29.57%, and 36.51%, respectively. Neither
• CD47CCR77CD62L nor CD8VCCR77CD62L populations were detected in the tumor samples.
• the average percentage of CD4 + T-cells expressing both CCR7 and CD62L was 28.75% while the average percentage of CD4 + T-cells expressing CD62L but not CCR7 was 25.54%.
• the average percentage of CCR7 + /CD62L + cells was 26.47% while the percentage of CD8 + T- cells expressing CD62L but not CCR7 was 23.82%.
• CCR7 + /CD62L + cells was 2.10%, expressing CCR7 but not CD62L was 29.49%, and expressing CD62L but not CCR7 was 6.04%.
• mice 6, 7, 8 and 10 were re-implanted subcutaneously (left, high axilla) on Day 44 post initial implant. On Day 81, Mice 6, 7, 8 and 10 were euthanized via C02 inhalation per client request. Mice 8 and 10 enlarged uterine horns at necropsy. Necropsies of Mice 6 and 7 were unremarkable.
• Necropsies were performed and the following findings were noted: enlarged spleens (10/10); white striated tissue located on the right ventricle (1/10); enlarged uterine horn (3/10); and 2/10 mice were noted as having slightly discolored "black” intestines.
• mice 4, 6, 8, and 9 were re-implanted subcutaneously (left, high axilla) on Day 44 post initial implant. On Day 81, Mice 4, 6, 8, and 9 were euthanized via C02 inhalation per client request. Mice 4, 6, 8, and 9 had unremarkable necropsies.
• the median time to evaluation size (750mm 3 ) was 18.4 days from the start of dosing resulting in a tumor growth delay of 2.5 days and the median post Day 9 tumor volume doubling time for Group 2 was 3.3 days, essentially identical to the control tumor doubling time.
• Treatment with GMI-1359 produced no regressions or tumor free survivors. All mice were identified with progressive disease (100%).
• Treatment with GMI-1359 produced no regressions or tumor free survivors. All mice were identified with progressive disease (100%).
• the median time to evaluation size was 14.3 days and the median post Day 9 tumor volume doubling time for Group 8 was 1.8 days. The median time to progression was on Day 14.5, and the progression free survival period was 5.5 days.
• the average percentage of T-cells detected in the Group 8 tumors via flow cytometry was 7.02% CD4 + cells and 15.61% CD8 + cells. There was an average of 2.66% myeloid-derived suppressor cells (MDSCs) and 2.93% regulatory T-cells (Tregs) in the tumors. The average percentages of cells expressing PD-1 , PD-L1 , and CTLA-4 were 23.39%, 34.44%, and 42.80%, respectively. Neither
• CD4 + /CCR7 + /CD62l_- nor CD8 + /CCR7 + /CD62L populations were detected in the tumor samples.
• the average percentage of CD4 + T-cells expressing both CCR7 and CD62L was 25.32% while the average percentage of cells expressing CD62L but not CCR7 was 31.43%.
• the average percentage of CCR7 + /CD62L + cells was 25.84% while the percentage of CD8 + T-cells expressing CD62L but not CCR7 was 25.65%.
• an average of 13.43% of the cells were CD4 + and 8.77% were CD8 + .
• the average percentage of MDSCs was 3.70% and Trees was 10.00%.
• the average percentages of cells expressing PD-1, PD-L1, and CTLA-4 were 5.53%, 81.50%, and 12.31%, respectively.
• the average percentage of CD4 + T-cells expressing both CCR7 and CD62L was 2.05%, expressing CCR7 but not CD62L was 33.36%, and expressing CD62L but not CCR7 was 5.42%.
• CCR7 + /CD62L + cells was 1.00%, expressing CCR7 + /CD62L ' was 27.95%, and expressing CD62L but not CCR7 was 2.94%.
• the median time to evaluation size (750mm 3 ) was 9.1 days from the start of dosing resulting in a tumor growth delay of 3.2 days and the median post Day 9 tumor volume doubling time for Group 3 was 3.2 days.
• the average percentage of T-cells detected in the Group 9 tumors via flow cytometry was 7.18% CD4 + cells and 9.99% CD8 + cells. There was an average of 3.14% myeloid-derived suppressor cells (MDSCs) and 6.81% regulatory T-cells (Tregs) in the tumors. The average percentages of cells expressing PD-1, PD-L1, and CTLA-4 were 26.57%, 28.63%, and 38.68%, respectively. Neither
• CD4 + /CCR7 + /CD62L- nor CD8 + /CCR7 + /CD62L populations were detected in the tumor samples.
• the average percentage of CD4* T-cells expressing both CCR7 and CD62L was 28.09% while the average percentage of cells expressing CD62L but not CCR7 was 31.62%.
• the average percentage of CCR77CD62L* cells was 23.50% while the percentage of CD8 + T-cells expressing CD62L but not CCR7 was 26.95%.
• the average percentage of CCR77CD62L* cells was 0.77%, expressing CCR7 but not CD62L was 31.59%, and expressing CD62L but not CCR7 was 1.48%.
• Treatment with anti-mPD-L1 , 10F.9G2 was well-tolerated.
• the median time to evaluation size (750mm 3 ) was >28 days from start of dosing resulting in a tumor growth delay of 11.7 days and the median post Day 9 tumor volume doubling time for Group 4 was 4.2 days.
• Treatment produced a 60% incidence of progressive disease (in Mice 1, 2, 3, 4, 5 and 9) and a 40% incidence of regressing disease (Mice 6, 7, 8 and 10) which all resulted in tumor-free survivors. These mice were later re-challenged and neither primary nor re-challenged implants had any regrowth.
• the median time to progression was on Day 12.8 and the progression free survival period was 3.8 days.
• the average percentage of T-cells detected in the Group 10 tumors via flow cytometry was 7.42% CD4 + cells and 15.52% CD8 + cells. There was an average of 2.69% myeloid-derived suppressor cells (MDSCs) and 1.69% regulatory T-cells (Tregs) in the tumors.
• MDSCs myeloid-derived suppressor cells
• Tregs regulatory T-cells
• the average percentages of cells expressing PD-1, PD-L1 , and CTLA-4 were 26.46%, 53.49%, and 43.76%, respectively. Neither
• CD4 + /CCR7 + /CD62I_- nor CD8 + /CCR7 + /CD62L populations were detected in the tumor samples.
• the average percentage of CD4* T-cells expressing both CCR7 and CD62L was 21.30% while the average percentage of cells expressing CD62L but not CCR7 was 34.21%.
• the average percentage of CCR7 + /CD62L + cells was 21.98% while the percentage of CD8* T-cells expressing CD62L but not CCR7 was 26.26%.
• the average percentage of T-cells detected in the Group 11 tumors via flow cytometry was 5.25% CD4 + cells and 8.22% CD8 + cells. There was an average of 3.29% myeloid-derived suppressor cells (MDSCs) and 1.79% regulatory T-cells ( rees) in the tumors. The average percentages of cells expressing PD-1, PD-L1 , and CTLA-4 were 25.85%, 55.52%, and 53.54%, respectively. Neither
• CD4 + /CCR7 + /CD62L- nor CD87CCR7 + /CD62L populations were detected in the tumor samples.
• the average percentage of CD4 + T-cells expressing both CCR7 and CD62L was 24.14% while the average percentage of cells expressing CD62L but not CCR7 was 31.16%.
• the average percentage of CCR77CD62L* cells was 17.51% while the percentage of CD8 + T-cells expressing CD62L but not CCR7 was 23.27%.
• CCR7 + /CD62L + cells was 5.68%, expressing CCR7 but not CD62L was 35.85%, and expressing CD62L but not CCR7 was 11.18%.
• the median time to evaluation size (750mm 3 ) was >29 days from the start of dosing resulting in a tumor growth delay of 13.5 days and the median post Day 9 tumor volume doubling time for Group 6 was 5.9 days.
• Treatment with GMI-1359 + anti-mPD-L1 , 10F.9G2 produced a 60% incidence of progressive disease, and a 30% incidence of regressing disease.
• Mice 4, 6, 8 and 9 were identified as tumor free survivors.
• Mouse 9 was unable to be identified as PD, SD, or RD because a tumor never became present and could be considered as a complete responder or in a rare incidence a no-take. The incidence of no-takes in control groups was 2% across 7 previous studies.
• the average percentage of T-cells detected in the Group 12 tumors via flow cytometry was 8.25% CD4 cells and 16.98% CD8 + cells. There was an average of 4.38% myeloid-derived suppressor cells (MDSCs) and 0.91% regulatory T-cells (Tregs) in the tumors. The average percentages of cells expressing PD-1, PD-L1, and CTLA-4 were 23.76%, 50.24%, and 45.71%, respectively. Neither
• CD4 + /CCR7 + /CD62L " nor CD8 + /CCR7 + /CD62L populations were detected in the tumor samples.
• the average percentage of CD4 + T-cells expressing both CCR7 and CD62L was 21.70% while the average percentage of cells expressing CD62L but not CCR7 was 25.84%.
• the average percentage of CCR7 + /CD62L + cells was 20.24% while the percentage of CD8* T-cells expressing CD62L but not CCR7 was 23.32%.
• CCR7 + /CD62L + cells was 2.77%, expressing CCR7 but not CD62L was 35.65%, and expressing CD62L but not CCR7 was 6.36%.
• FIG. 19 Tumor Growth Delay column, provides the results, in days, that each treatment delayed tumor growth.
• Treatment with GMI-1359 alone did not produce a statistically significant (p>0.05) anti-tumor effect and all animals were identified with progressive disease with a minimal tumor growth delay of 2.5 days.
• Treatment with anti-mPD-L1 as a single agent produced a statistically significant (p ⁇ 0.05) anti-tumor effect where 30% of the mice were identified as having regressing disease and 40% as tumor free survivors with a median tumor growth delay of 11.7 days.
• mice In Group 4 (anti-mPD-L1 alone) and Group 6 (GMI-1359 + anti-mPD-L1) four mice each were re-implanted subcutaneously (left, high axilla) on Day 44. All re- challenged mice were held out to Day 81 when they were euthanized per client request as no re-growth occurred. That is, as indicated in Figure 20, mice that achieved a complete response, even those with a quicker complete response due to the treatment combining both GMI-1359 and anti-mPD-U, rejected a subsequent challenge to CT-26.
• mice in group 1 serum control
• group 2 with single agent GMI-1359
• mice in group 1 were all identified with progressive disease (see Figure 19).
• treatment with anti- mPD-L1 alone (group 4) or in combination with GMI-1359 (group 6) produced a 40% complete response (CR), or tumor free survivor (TFS), rate.
• CR tumor free survivor
• group 4 The median time to CR was shorter when anti-mPD-L1 was combined with GMI-1359 (group 6) compared to anti-mPD-L1 alone (group 4).
• the median time to CR for treatment group 6, treated with anti-mPD-L1 was combined with GMI-1359, versus 23 days for group 4, treated with anti-mPD-L1 alone (p ⁇ 0.0471).
• Evaluation of tumor infiltrating cells showed that combination therapy with GMI-1359 and anti-mPD-L1 antibody (group 12) reduced the percentage of T reg compared to treatment with saline (group 7), GMI-1359 (group 8), or the anti-mPD-L1 antibody (group 10) as single treatments (0.9% vs. 3.3%, 2.9% and 1.9%, respectively (see Figure 10)).
• No other T cell subsets were affected (see, e.g., Figures 7 and 8 (other T cells) as compared to Figure 10 (T reg cells)).
• the median percentage of T reg were unaffected by any of the treatments (see, e.g., Figure 14) and suggest that the reduction in intra-tumoral by combined treatment with anti-PD-L1 and the heterobifunctional E-selectin and CXCR4 receptor inhibitor GMI-1359 was an attenuated response to maintenance and homing signals in the tumor microenvironment.
• lymphocytes were found to differ from the splenic lymphocytes in that, within the tumor, no CD4 + /CCR7 + /CD62L " or CD8 + /CCR7 + /CD62L- populations could be found whereas, within the spleen, these populations were quite abundant.
• T reg T regulatory
• TIL CD4 + /CCR77CD62L + appear to decrease with anti-mPD-L1 or GMI-1359 and anti-mPD-L1 treatments.
• TIL PD-L1 levels increase with anti-mPD-L1 alone, GMI-1359 + isotype control and GMI-1359 + anti- mPD-L1 treatments as compared to vehicle, GMI-1359 alone, or isotype control alone, respectively.
• Figure 7 provides a graph of the percentage of
• FIG. 11 provides a graph of the percentage of CD47CCR7 + /CD62L + in the spleens of the individuals in experimental groups 7-12.
• the average percentage of Treg cells remained the same when the mice were treated with the anti-mPD-L1 antibody (see, e.g., exemplary scatter plot for Group 10, Figure 15A) or the GMI- 359 plus the isotype control antibody (see, e.g., exemplary scatter plot for Group 11, Figure 15B). However, when the mice were treated with a combination of GMI-1359 and anti-mPD-L1 antibody (see, e.g., exemplary scatter plot for Group 12, Figure 15C), the average percentage of ⁇ cells decreased.
• Figure 16A is a representative scatter plot showing the CD47CCR77CD62L cells in spleens of an individual (mouse 4, group 8) treated with GMI-1359.
• Figure 16B is a representative scatter plot showing the
• CD4 + /CCR7 + /CD62L + cells in spleens of an individual (mouse 1, group 12) treated with GMI-1359 and anti-PD-L1 antibody treatment are shown in FIG. 1 .
• These graphs indicate that GMI- 1359 in combination with the isotype control antibody affected the percentage of CD4 + /CCR7 + /CD62L + cells while GMI- 359 as a single agent did not.
• FIG. 12 provides a graph of the percentage of CD8 + /CCR77CD62L + cells in the spleens in experimental groups 7 through 12.
• the mice were treated with the anti-mPD-L1 antibody (Group 10) or GMI-1359 together with the isotype control antibody (Group 11) the average percentage of CD87CCR77CD62L* cells increased compared to the vehicle control (Group 7).
• Figure 17A shows a representative scatter plot of data from Mouse 4 in Group 7
• Figure 17B shows a representative scatter plot of data from Mouse 3 in Group 10.
• mice with stable disease in Group 12 had statistically significantly lower percentages of MDSCs than the mice with progressive disease (Figure 13, providing a graph of the percentage of CD11b + /GR1 + (MDSCs) in Spleens in groups 7-12). Representative scatter plots showing these differences are shown in Figures 18A-C.
• Mouse 3 from Group 9 represents all of those from Group 9
• Mouse 3 from Group 12 represents those mice from Group 12 with stable disease
• Figure 21 relates to an experiment carried out to determine the competitive binding activity (IC50) of GMI-1359 against E-selectin and CXCR4.
• IC50 competitive binding activity
• GM 1-1359 was assessed for inhibition of sialyl Le x binding to immobilized E-selectin and a-CXCR4 antibody binding to Raji cells.
• the inhibition assay to screen G I-1359 as an antagonist of E-selectin was a competitive binding assay, which allowed the determination of IC 50 values.
• Human E-selectin/lg chimera was immobilized by incubation at 37 °C for 2 hour in 96-well microtiter plates. To reduce nonspecific binding, BSA was added to each well and incubated at room temperature for 2 hours.
• the inhibition assay to screen GMI-1359 as an antagonist of CXCR4 was a flow based competitive binding assay, which allowed the determination of IC 5 o values.
• Raji cells (ATCC number TIB-152) were washed twice with Hanks Balanced Saline Solution (HBSS) containing 0.05% bovine serum albumin (BSA). After the second wash, the cells were resuspended to about 2.5 x 10 6 cells per mL and 80 ⁇ of cells (approximately 2 x 10 5 cells) were added to BD 2063 tubes. Next, 10 ⁇ of either GMI-1359 or HBSS/BSA (as a negative control) were added to the cells and the tube was placed at room temperature for 10 minutes.
• HBSS Hanks Balanced Saline Solution
• BSA bovine serum albumin
• a phycoerythrin-conjugated anti-CXCR4 antibody (R&D Systems, FAB170P) or as a negative control
• 10 ⁇ of an isotype control antibody (R&D Systems, IC003P) was added to the cells with HBSS/BSA.
• the antibodies were allowed to bind to the cells for 1 hour at 4°C.
• 2 mL of cold HBSS/BSA were added to all the tubes, and the cells were pelleted by centrifugation at 250 x g for 10 minutes. The supernatants were discarded and the cell pellets were resuspended in 1 mL of HBSS/BSA.
• the cells were pelleted again as before, suspended in 150 ⁇ of HBSS/BSA and fixed by the addition of 150 ⁇ of 2% formaldehyde. Binding of the anti-CXCR4-PE antibody to the cells was assessed by flow cytometry, and the median fluorescent intensity was determined . The median fluorescent intensities were plotted as a function of increasing concentration of GMI-1359 using GraphPad Prism software, and an IC50 (defined as the concentration of GMI-1359 resulting in a 50% inhibition of
• Figure 22 relates to an experiment carried out to determine percentages of CD4+, CD8+, and Regulatory T cells (CD4+, FoxP3+, and CD25+) in spleen and tumor tissue samples, in vivo, on study day 15, from each treatment group. Details of the experimental treatments for each of the groups are provided above with respect to Example 1. [0240] Twenty-four hours following the final dose of GMI-1359, five mice from each treatment group were euthanized and spleens and tumors were processed for flow cytometry. Tumors were dissociated according to Miltenyi Dissociation Protocol for soft tumors. Single cell suspensions from spleen were obtained by maceration.
• Figure 22 shows the results for percentage of total CD4+ and CD8+ lymphocytes and regulatory T cells.
• Figure 23 relates to an experiment carried out to determine the ratio of CD8/regulatory T cells in spleen and tumor tissue samples, in vivo, on day 15.
• mice from each treatment group were euthanized and spleens and tumors were processed for flow cytometry. Tumors were dissociated according to Miltenyi Dissociation Protocol for soft tumors. Single cell suspensions from spleen were obtained by maceration.
• rat anti-CD4 FITC conjugate rat anti-CD8a APC-AlexaFluor 750 conjugate
• rat anti-CD25 PE conjugate clone PC61 5.3
• mouse anti-FoxP3 APC conjugate clone 3G3.
• Figures 24A and 24B relate to an experiment carried out to compare the mean tumor burden and the responsiveness to treatments in each group. Details of the experimental treatments for each of the groups are provided above with respect to Example 1.
• Tumor volumes were estimated from caliper measurements recorded three times weekly beginning at the start of treatment.
• Figure 24A shows the primary endpoints used to evaluate efficacy: tumor growth delay; the number of tumor-free survivors at the end of the study; the incidences of progressive disease, stable disease, and regressing disease; and the response. Additionally, Figure 24B shows the number of days post tumor implant on the x-axis and the mean tumor burden (mm 3 ) in each treatment group on the y-axis.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=59687019

Family Applications (1)

Country Status (4)

Cited By (9)

Citations (4)

Family Cites Families (239)

• 2017
  • 2017-08-07 JP JP2019506516A patent/JP2019524791A/ja active Pending
  • 2017-08-07 WO PCT/US2017/045690 patent/WO2018031445A1/en not_active Ceased
  • 2017-08-07 US US16/323,685 patent/US11433086B2/en active Active
  • 2017-08-07 EP EP17755592.7A patent/EP3497131B1/en active Active
• 2022
  • 2022-07-28 US US17/876,213 patent/US20230127765A1/en not_active Abandoned

Patent Citations (5)

Non-Patent Citations (36)

Also Published As

Similar Documents

Legal Events